Medical Enzymes and Nektar Therapeutics announce PEGylation cooperation

26-Sep-2006

Medical Enzymes AG announced the signing of a license agreement with Nektar Therapeutics to use Nektar's proprietary PEGylation for Medical Enzymes' lead product GlutaDON®. GlutaDON® is currently in clinical development for the treatment of different solid tumours.

Under the terms of the agreement, Nektar will provide Medical Enzymes with its Advanced PEGylation technology for use in GlutaDON® and Medical Enzymes will pay Nektar an upfront fee, milestone payments, manufacturing revenues, and royalties on product sales.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances